赛诺医疗(688108.SH)公告称，公司收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册 证》，注册证编号为国械注准20263130263，产品名称为药物洗脱支架系统。该产品适用于改善局部缺 血型心脏病患者的血管狭窄症状，有效期至2031年2月2日。这是赛诺医疗自主研发并生产的冠脉支架类 产品，获批将进一步丰富公司的产品组合，提升核心竞争力。但该产品后续尚需进行医疗器械生产许可 变更后方可生产，实际销售情况取决于市场推广效果，对公司未来业绩的具体影响尚无法预测。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

赛诺医疗公告，近日，公司收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》。产品 名称为药物洗脱支架系统，适用于改善局部缺血型心脏病患者的血管狭窄症状。该产品为赛诺医疗自主 研发并生产，其获批将丰富公司产品组合，满足市场需求，提升核心竞争力。 ...

结构及组成：药物洗脱支架系统由药物涂层支架和快速交换球囊导管输送系统组成。药物涂层支架以 L605钴铬合金支架为基体，表面涂覆底部涂层和含药高分子涂层。底部涂层材料为聚甲基丙烯酸丁酯 （PBuMA），该涂层不可降解；药物涂层由雷帕霉素药物和聚乳酸-羟基乙酸（PLGA）组成，为可降 解涂层。支架药物剂量密度为1.20μg/mm2；载药量为59μg～324μg。输送系统由TIP头、球囊、 Marker、球囊内管、球囊外管和手柄组成。产品经过电子束灭菌，一次性使用。货架有效期18个月。 适用范围：该产品适用于参考1.血管直径为2.25～4.00mm，适用的病变长度≤40mm；2.参考血管直径为 4.50～5.00mm，适用的病变长度≤30mm；用于改善局部缺血型心脏病患者的血管狭窄症状。 格隆汇2月4日丨赛诺医疗(688108.SH)公布，近日，公司收到国家药品监督管理局颁发的《中华人民共 和国医疗器械注册证》，产品名称：药物洗脱支架系统，注册证编号：国械注准20263130263。 本次获得《医疗器械注册证》的药物洗脱支架系统，是由我公司自主研发并进行生产的一款冠脉支架类 产品。该产品是一个预装的药物洗脱支架系统 ...

格隆汇2月4日丨赛诺医疗(688108.SH)公布，近日，公司收到国家药品监督管理局颁发的《中华人民共 和国医疗器械注册证》，产品名称：药物洗脱支架系统，注册证编号：国械注准20263130263。 结构及组成：药物洗脱支架系统由药物涂层支架和快速交换球囊导管输送系统组成。药物涂层支架以 L605钴铬合金支架为基体，表面涂覆底部涂层和含药高分子涂层。底部涂层材料为聚甲基丙烯酸丁酯 （PBuMA），该涂层不可降解；药物涂层由雷帕霉素药物和聚乳酸-羟基乙酸（PLGA）组成，为可降 解涂层。支架药物剂量密度为1.20μg/mm2；载药量为59μg～324μg。输送系统由TIP头、球囊、 Marker、球囊内管、球囊外管和手柄组成。产品经过电子束灭菌，一次性使用。货架有效期18个月。 适用范围：该产品适用于参考1.血管直径为2.25～4.00mm，适用的病变长度≤40mm；2.参考血管直径为 4.50～5.00mm，适用的病变长度≤30mm；用于改善局部缺血型心脏病患者的血管狭窄症状。 本次获得《医疗器械注册证》的药物洗脱支架系统，是由我公司自主研发并进行生产的一款冠脉支架类 产品。该产品是一个预装的药物洗脱支架系统 ...

8月19日，赛诺医疗今日收盘40.42元，下跌2.56%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到2738.89倍，总市值168.17亿元。 来源：金融界 赛诺医疗科学技术股份有限公司的主营业务是高端介入医疗器械研发、生产、销售。公司的主要产品是 生物降解药物涂层冠脉支架系统、药物洗脱支架系统、非顺应性PTCA球囊扩张导管、PTCA球囊扩张 导管、非顺应性球囊扩张导管、冠脉球囊扩张导管、冠状动脉棘突球囊扩张导管、延长导管、颅内药物 洗脱支架系统、颅内取栓支架、颅内球囊扩张导管、负压吸引泵、一次性使用无菌吸引延长管、远端通 路导管、颅内血栓抽吸导管、微导管、远端通路导引导管、导引导管、桡动脉通路导引系统、输送导 管、球囊导引导管。 最新一期业绩显示，2025年一季报，公司实现营业收入1.01亿元，同比10.75%；净利润296.93万元，同 比277.50%，销售毛利率59.66%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13赛诺医疗2738.8911227.6219.32168.17亿行业平均 59.4955.005.10121.17亿行业中值40.1939.642.955 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sainuo Medical, indicating a significant increase in net profit and a high PE ratio compared to industry averages [1][2] - As of March 31, 2025, Sainuo Medical had 11,044 shareholders, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, and sales of high-end interventional medical devices, with key products including biodegradable drug-coated coronary stent systems and various types of balloon dilation catheters [1] Group 2 - In the first quarter of 2025, Sainuo Medical reported revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.9693 million yuan, reflecting a substantial year-on-year growth of 277.50% [2] - The company's gross profit margin stood at 59.66%, indicating strong profitability relative to its revenue [2] - Sainuo Medical's rolling PE ratio is 850.40, significantly higher than the industry average of 53.52 and the median of 37.14, positioning it at 121st in the industry ranking [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Sino Medical, noting its significant increase in stock price and high PE ratio compared to industry averages [1][2] - As of July 18, Sino Medical's stock closed at 12.12 yuan, up 7.73%, with a rolling PE ratio of 821.26, marking a new low in 285 days and a total market capitalization of 5.043 billion yuan [1] - The average PE ratio for the medical device industry is 52.34, with a median of 36.99, placing Sino Medical at the 121st position in the industry ranking [1][2] Group 2 - For Q1 2025, Sino Medical reported revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.9693 million yuan, reflecting a substantial year-on-year growth of 277.50% [2] - The company's gross profit margin stands at 59.66%, indicating strong profitability relative to its revenue [2] - As of March 31, 2025, Sino Medical had 11,044 shareholders, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Core Viewpoint - Sino Medical reported a closing price of 10.69 yuan, down 1.75%, with a rolling PE ratio of 724.36 times, and a total market value of 4.448 billion yuan [1] Company Summary - Sino Medical's main business focuses on the research, development, production, and sales of high-end interventional medical devices [1] - Key products include biodegradable drug-coated coronary stent systems, drug-eluting stent systems, non-compliant PTCA balloon dilatation catheters, and various other specialized medical devices [1] Financial Performance - For Q1 2025, the company achieved an operating income of 101 million yuan, representing a year-on-year increase of 10.75% [2] - The net profit for the same period was 2.9693 million yuan, showing a significant year-on-year increase of 277.50% [2] - The sales gross margin stood at 59.66% [2] Industry Comparison - The average PE ratio for the medical device industry is 49.45 times, with a median of 35.92 times, positioning Sino Medical at 121st place within the industry [1] - The company's static PE ratio is 296.94 times, and the price-to-book ratio is 5.11 [2]